MD Anderson Research Highlights for December 13, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include a novel blood-based test to predict lung cancer relapses...
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
ABSTRACT: LBA-2
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
ABSTRACT: 620
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged...
MD Anderson Research Highlights: ASH 2023 Special Edition
ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983
SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features...
MD Anderson Research Highlights for November 15, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights: SITC 2023 Special Edition
ABSTRACTS: 1534, 777, 1328, 1526, 1330, 545
The University of Texas MD Anderson Cancer Center’s Research...
MD Anderson Research Highlights for October 25, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Lactate-producing bacteria inside tumors promote resistance to radiation therapy
Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance...
MD Anderson Research Highlights: ESMO 2023 Special Edition
ABSTRACTS: LBA71, 1088MO, 95MO, LBA48, 1082O, 1085O, LBA34, 243MO
The University of Texas MD Anderson Cancer Center’s Research Highlights...
MD Anderson hosts 2023 Leading Edge of Cancer Research Symposium
The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring...
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for September 21, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for August 30, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer...
MD Anderson receives nearly $4.9 million in CPRIT funding for cancer prevention programs and recruitment
The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research...
MD Anderson Research Highlights for August 16, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for July 19, 2023
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Largest-ever atlas of normal breast cells brings unprecedented insights into mammary biology
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine...
MD Anderson Research Highlights for June 27, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting...
Mutant KRAS regulates Y chromosome gene in colorectal cancer, driving metastasis and inhibiting anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated...
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights: ASCO 2023 Special Edition
ABSTRACTS: 398868, 425082, 6546, 3501, 6008, 9502, 9011, 9008
CHICAGO ― The University of Texas MD Anderson Cancer Center’s Research...
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy...
MD Anderson Research Highlights for May 10, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for April 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
ABSTRACT: 5788
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas...
MD Anderson Research Highlights AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe...
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical...
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson receives nearly $19.4 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research...
Lung cancer study finds new target for treatment resistance after EGFR inhibitors
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells...
MD Anderson Research Highlights for February 1, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...